Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,172.00
Ask: 12,174.00
Change: -18.00 (-0.15%)
Spread: 2.00 (0.016%)
Open: 12,304.00
High: 12,356.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU gets 107 million vaccine doses by end of week; finds no Astra risk

Wed, 31st Mar 2021 14:53

(Alliance News) - EU member states will have received a total of 107 million doses of coronavirus vaccine by the end of this week, a European Commission spokeswoman said Wednesday.

Also, the EU's drug regulator said, experts probing links between the AstraZeneca PLC coronavirus vaccine and blood clots have found no specific risk factors, including age, but are carrying out further analysis.

"At present the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events," the European Medicines Agency said in a statement.

Deliveries for the first three months of the year are made up of 67.2 million doses from BioNtech SE-Pfizer Inc, 29.8 million from Astra, and 9.8 million from Moderna Inc, the commission said. 

The overall figure was revised down dramatically after the Anglo-Swedish pharma giant AstraZeneca slashed the number it was providing from a contracted 120 million doses.

The production shortfall has contributed to a stuttering start to the EU's vaccination campaign that has seen the bloc lag behind countries including the US, Britain, and Israel.

Deliveries are expected to pick up considerably in the second quarter of the year, with the commission saying it should receive at least 300 million doses by the end of June.

That figure should include 55 million shots of the single-dose Johnson & Johnson jab, which officials hope will help speed up vaccination rates. 

EU chief Ursula von der Leyen insists the 27-nation bloc remains on course to meet a target to inoculate 70% of adults "by the end of summer". 

That is despite it being set to miss another stated ambition to have 80% of over-80s and health workers vaccinated by the end of March. 

The shortfall in deliveries from AstraZeneca has led to a row with Britain, as both sides scramble to ensure they get doses. 

Von der Leyen warned last week that the bloc would ban drug firms exporting vaccines until they made good on promised deliveries to the EU. 

There have also been calls from five member states led by Austria for some doses to be redistributed within the EU over fears of shortfalls in some capitals. 

On Tuesday, Austria said it had become the latest EU country to open talks with Russia about securing deliveries of its Sputnik V vaccine.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
Today 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.